Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY)

CUSIP: 75943R102

Q1 2023 13F Holders as of 31 Mar 2023

Holder snapshot 7 signals
Share change
+3,028,199
Put/Call ratio
81%
SEC-reported price per share
$16.47
Number of holders
155
Value change
+$53,163,179
Number of buys
74
Open additional details 1 more signal available
Number of sells
82
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
218,181,818

Security key

75943R102

Report period

Q1 2023

Institutions

155

Top holders

10

Ownership snapshot

Top reported holders of RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
SB INVESTMENT ADVISERS (U...
Disclosed value leader
SB INVESTMENT ADVISERS (U...
Comparable rows
0/15
Latest evidence
31 Dec 2022
13F Highest disclosed value: $416,900,147 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

SB INVESTMENT ADVISERS (UK) LTD has the largest disclosed position value at $416.9M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens SB INVESTMENT ADVISERS (UK) LTD's linked filing trail.
Disclosed position value Top 5
SB INVESTMENT ADVISERS (UK) LTD $416.9M
VANGUARD GROUP INC $155.14M
FMR LLC $145.42M
BlackRock Finance, Inc. $119.49M
STATE STREET CORP $93.59M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
SB INVESTMENT ADVISERS (UK) LTD
13F
Company
13F
—
denominator unverified
$416,900,147
27,904,963 shares
— 31 Dec 2022
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$155,140,217
10,384,218 shares
— 31 Dec 2022
FMR LLC
13F
Company
13F
—
denominator unverified
$145,423,690
9,733,848 shares
— 31 Dec 2022
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$119,489,896
7,997,985 shares
— 31 Dec 2022
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$93,591,585
6,264,497 shares
— 31 Dec 2022
PRICE T ROWE ASSOCIATES INC /MD/
13F
Company
13F
—
denominator unverified
$67,126,000
4,493,004 shares
— 31 Dec 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
155
Shares
131,039,866
Rows available
155
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2023 vs Q1 2023 Across Filers

Q1 2023 holders
155
Q1 2023 holders
155
Holder diff
0
Investor Q1 2023 Shares Q1 2023 Shares Share Diff Share Chg % Q1 2023 value Q1 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .